ICOS ligand costimulation is required for T-cell encephalitogenicity

被引:69
|
作者
Sporici, RA
Beswick, RL
von Allmen, C
Rumbley, CA
Hayden-Ledbetter, M
Ledbetter, JA
Perrin, PJ
机构
[1] Univ Penn, Sch Med, Dept Med, Pulm Allergy & Crit Care Sect, Philadelphia, PA 19104 USA
[2] Pacific NW Res Inst, Seattle, WA 98122 USA
关键词
EAE/MS; costimulatory molecules; T-lymphocytes; immunotherapy;
D O I
10.1006/clim.2001.5074
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The interaction of ICOS with its ligand on APC provides a costimulatory signal to previously activated T-cells. In these studies, we blocked the ICOS:ICOS ligand interaction with ICOS-Ig during the in vitro activation of AMP-reactive transgenic CD4(+) T-cells. The presence of ICOS-Ig in these cultures inhibited the ability of the transgenic T-cells to transfer EAE, although they entered the brains of the recipient mice. ICOS-Ig increased apoptosis in the transgenic T-cells, especially in the memory population. This enhanced apoptosis was accompanied by an increase in the BAX/BCL-2 mRNA ratio. ICOS-Ig did not prevent IL2 production, demonstrating that IL-2 production is ICOS ligand independent. IFN-gamma and IL-10 production by the transgenic T-cells, however, was suppressed. Finally, ICOS-Ig injection into mice after the first signs of EAE ameliorated clinical disease. Therefore, ICOS-Ig provides a signal distinct from CD28 costimulation that is required for the activation and viability of encephalitogenic T-cells. (C) 2001 Academic Press.
引用
收藏
页码:277 / 288
页数:12
相关论文
共 50 条
  • [21] CAR T-cell therapy for multiple myeloma
    Zhou, X.
    Einsele, H.
    Danhof, S.
    INTERNIST, 2021, 62 (06): : 605 - 610
  • [22] ICOS controls Foxp3+ regulatory T-cell expansion, maintenance and IL-10 production during helminth infection
    Redpath, Stephen A.
    van der Werf, Nienke
    Cervera, Ana M.
    MacDonald, Andrew S.
    Gray, David
    Maizels, Rick M.
    Taylor, Matthew D.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2013, 43 (03) : 705 - 715
  • [23] Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner
    Shi, Lewis Zhichang
    Goswami, Sangeeta
    Fu, Tihui
    Guan, Baoxiang
    Chen, Jianfeng
    Xiong, Liangwen
    Zhang, Jan
    Tang, Derek Ng
    Zhang, Xuejun
    Vence, Luis
    Blando, Jorge
    Allison, James P.
    Collazo, Renata
    Gao, Jianjun
    Sharma, Padmanee
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (11) : 1803 - 1812
  • [24] For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
    Singh, Kirit
    Hotchkiss, Kelly M.
    Mohan, Aditya A.
    Reedy, Jessica L.
    Sampson, John H.
    Khasraw, Mustafa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (11)
  • [25] T cell costimulation, checkpoint inhibitors and anti-tumor therapy
    Dipankar Nandi
    Sanmoy Pathak
    Taru Verma
    Madhulika Singh
    Avik Chattopadhyay
    Samriddhi Thakur
    Abinaya Raghavan
    Abhijeet Gokhroo
    Journal of Biosciences, 2020, 45
  • [26] T cell costimulation, checkpoint inhibitors and anti-tumor therapy
    Nandi, Dipankar
    Pathak, Sanmoy
    Verma, Taru
    Singh, Madhulika
    Chattopadhyay, Avik
    Thakur, Samriddhi
    Raghavan, Abinaya
    Gokhroo, Abhijeet
    Vijayamahantesh
    JOURNAL OF BIOSCIENCES, 2020, 45 (01)
  • [27] NK/T-cell lymphomas
    Tse, Eric
    Kwong, Yok-Lam
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (03) : 253 - 261
  • [28] T-CELL IMMUNOTHERAPY OF CANCER
    MELIEF, CJM
    KAST, WM
    RESEARCH IN IMMUNOLOGY, 1991, 142 (5-6): : 425 - 429
  • [29] Treatment of T-cell lymphoma
    Hotta, T
    HEMATOLOGY, 2005, 10 : 193 - 196
  • [30] T-cell therapy for cancer
    Barrett, John
    Bollard, Catherine M.
    IMMUNOTHERAPY, 2012, 4 (04) : 347 - 350